A comparison between simplified and intensive dose-titration algorithms using air inhaled insulin for insulin-naive patients with type 2 diabetes in a randomized noninferiority trial

Diabetes Technology and Therapeutics

Volumn 11, Issue SUPPL. 2, 2009, Pages

  Mathieu, C ^a   Cuddihy, R ^b   Arakaki, R F ^c   Belin, R M ^d   Planquois, J M ^d   Lyons, J N ^d   Heilmann, C R ^d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b INTERNATIONAL DIABETES CENTER   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AIR INHALED INSULIN; INSULIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG FEVER; DRUG METABOLISM; FEMALE; GLUCOSE CLAMP TECHNIQUE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NECK PAIN; NORMAL HUMAN; PRIORITY JOURNAL; RHINOPHARYNGITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADMINISTRATION, INHALATION; ADULT; AGED; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; VITAL CAPACITY;

EID: 70349451912     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0036     Document Type: Article

References (29)

1. Riddle MC: Starting and advancing insulin for type 2 diabetes: algorithms and individualized methods are both necessary. J Clin Endocrinol Metab 2008;93:372-374
2. Cryer PE: Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002;45:937-948
3. McCrimmon RJ, Frier BM: Hypoglycaemia, the most feared complication of insulin therapy. Diabetes Metab 1994;20: 503-512
4. Brown JB, Nichols GA, Perry A: The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-1540
5. Rosenstock J, Muchmore D, Swanson D, Schmitke J: AIR Inhaled Insulin System: a novel insulin-delivery system for patients with diabetes. Expert Rev Med Devices 2007;4: 683-692
6. Rave K, Bott S, Heinemann L, Sha S, Becker RH, Willavize SA, Heise T: Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005;28:1077-1082
7. Garg S, Rosenstock J, Silverman BL, Sun B, Konkoy CS, de la Peñ a A, Muchmore DB: Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 2006;49: 891-899
8. D'Orazio P, Burnett RW, Fogh-Andersen N, Jacobs E, Kuwa K, Kulpmann WR, Larsson L, Lewenstam A, Maas AH, Mager G, Naskalski JW, Okorodudu AO; IFCC-SD-WGSEPOCT: Approved IFCC recommendation on reporting results for blood glucose: International Federation of Clinical Chemistry and Laboratory Medicine Scientific Division, Working Group on Selective Electrodes and Point-of-Care Testing (IFCC-SD-WG-SEPOCT). Clin Chem Lab Med 2006; 44:1486-1490
9. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE system of intensive diabetes self-management 2002 update. AACE Diabetes Guidelines. Endocr Pract 2002;8(Suppl 1):40-82
10. Heise T, Bott S, Tusek C, Stephan JA, Kawabata T, Finco- Kent D, Liu C, Krasner A: The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. Diabetes Care 2005;28:2161-2169
11. Moxness M, Foley J, Stene M, Finco-Kent D, Bedian V, Krasner A, Kawabata T: Development and validation of radioligand binding assays to measure total, IgA, IgE, IgG, and IgM insulin antibodies in human serum. Ann N Y Acad Sci 2003;1005:265-268
12. American Thoracic Society: Standardization of spirometry- 1994 update. Am J Respir Crit Care Med 1995;152:1107-1136
13. Akritas MG, Arnold SF, Brunner E: Nonparametric hypotheses and rank statistics for unbalanced factorial designs. J Am Stat Assoc 1997;92:258-265
14. Cefalu WT, Wang ZQ: Clinical research observations with use of Exubera in patients with type 1 and 2 diabetes. Diabetes Technol Ther 2007;9(Suppl 1):S-28-S-40
15. Quattrin T, Bélanger A, Bohannon NJ, Schwartz SL: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2622-2627
16. Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE, Gerstein HC; Inhaled Insulin Phase III Type 1 Diabetes Study Group: Use of inhaled insulin in a basal=bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005;28:1630-1635
17. Be langer A: Efficacy and safety of inhaled insulin (Exubera-) compared to conventional subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomised comparative trial [full poster provided by Pfizer] [abstract 808]. In: 38th Annual European Association for the Study of Diabetes Meeting, Budapest, 2002. http:==www. easd.org (accessed July 5, 2009)
18. Cefalu WT, Skyler JS, Kourides IA, Landschulz WH, Balagtas CC, Cheng S, Gelfand RA; Inhaled Insulin Study Group: Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001;134:203-207
19. Hermansen J, Ronnemaa T, Petersen AH, Adamson U: Intensive treatment with pulmonary insulin using the AERx [reg] insulin diabetes management system-a proof of concept trial in type 2 diabetic patients [abstract]. Diabetes 2002; 51(Suppl 2):194
20. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson JL, Levin SR: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27:2356-2362
21. Brain JD: Unlocking the opportunity of tight glycaemic control. Inhaled insulin: safety. Diabetes Obes Metab 2005; 7:S14-S18
22. Rave K, Nosek L, Heinemann L, Gonzales C, Ernest CS, Chien J, Muchmore D: Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles. Diabet Med 2004;21:763-768
23. Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, Gelfand RA: Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001;357:331-335
24. Bindra S, Cefalu WT: Exubera. Inhale therapeutic systems. Curr Opin Investig Drugs 2002;3:758-762
25. Rosenstock J, Bergenstal R, Defronzo RA, Hirsch IB, Klonoff D, Boss A, Kramer D, Petrucci R, Yu W, Levy B; 0008 Study Group: Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulinnaive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care 2008;27:2177-2182
26. Bergenstal RM, Johnson M, Powers MA, Wynne A, Vlajnic A, Hollander P, Rendell M: Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 2008;31:1305-1310
27. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T: Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008;371:1073-1084
28. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A: Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-265
29. Action to Control Cardiovascular Risk in Diabetes Study Group, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559